Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lords and Company Worldwide Holdings (XCNQ:LRDS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lords and Company Worldwide Holdings EBITDA Margin % Related Terms
Lords and Company Worldwide Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lords and Company Worldwide Holdings EBITDA Margin % Chart
XCNQ:LRDS vs ZTS, CTLT, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lords and Company Worldwide Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lords and Company Worldwide Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lords and Company Worldwide Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lords and Company Worldwide Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lords and Company Worldwide Holdings (XCNQ:LRDS) has a EBITDA Margin % of 117.86% as of Aug. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lords and Company Worldwide Holdings and its competitors.
Is Lords and Company Worldwide Holdings' EBITDA Margin % too high?
Lords and Company Worldwide Holdings' current EBITDA Margin % is 117.86%. The Drug Manufacturers industry median EBITDA Margin % is 11.89. Lords and Company Worldwide Holdings' value of 117.86% is 891.3% above this industry median.
How does Lords and Company Worldwide Holdings' EBITDA Margin % compare to ZTS and CTLT?
Lords and Company Worldwide Holdings' EBITDA Margin % of 117.86% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 11.89. Lords and Company Worldwide Holdings' value of 117.86% is 891.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lords and Company Worldwide Holdings's current EBITDA Margin % of 117.86% is 891.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lords and Company Worldwide Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lords and Company Worldwide Holdings's current EBITDA Margin % is 117.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lords and Company Worldwide Holdings stock overvalued right now?
Lords and Company Worldwide Holdings (XCNQ:LRDS) has a current EBITDA Margin % of 117.86%. The current EBITDA Margin % is 117.86% and 891.3% above the Drug Manufacturers industry median of 11.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lords and Company Worldwide Holdings (XCNQ:LRDS), the current EBITDA Margin % is 117.86% as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lords and Company Worldwide Holdings Corp develops, produces, and markets lifestyle apparel and natural health products through its e-Commerce platform to retail, B2B and B2C, consumers in North America and Europe utilizing its proprietary direct-to-consumer platform. Through continuous strategic white labelling, Lords has a footprint in the nutraceutical product markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:LRDS has been successfully added to your 
